6-oxo-1,4,5,6-tetrahydrocyclopenta [b] pyrrol-2-carboxylic acid | 1041430-01-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 6-oxo-1,4,5,6-tetrahydrocyclopenta [b] pyrrol-2-carboxylic acid
• 英文别名: 6-oxo-1,4,5,6-tetrahydrocyclopenta[b]pyrrole-2-carboxylic acid；6-oxo-1,4,5,6-tetrahydrocyclopenta[b]pyrrol-2-carboxylic acid；6-oxo-4,5-dihydro-1H-cyclopenta[b]pyrrole-2-carboxylic acid
• CAS: 1041430-01-6
• 化学式: C₈H₇NO₃
• 分子量: 165.148
• InChiKey: HOCJDKCIZQKRMP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  70.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  N-甲基哌嗪 、 6-oxo-1,4,5,6-tetrahydrocyclopenta [b] pyrrol-2-carboxylic acid 在 N-甲基吗啉 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 以72%的产率得到2-(4-methylpiperazine-1-carbonyl)-4,5-dihydro-1H-cyclopenta[b]pyrrol-6-one
  参考文献：
  名称：

  EP2460794

  摘要：

  公开号：
• 作为产物：
  描述：

  tetrahydro-cyclopenta[b]pyrrole-2-carboxylic acid ethyl ester 在 水 、 2,3-二氯-5,6-二氰基-1,4-苯醌 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 8.0h， 生成 6-oxo-1,4,5,6-tetrahydrocyclopenta [b] pyrrol-2-carboxylic acid
  参考文献：
  名称：

  EP2460794

  摘要：

  公开号：

文献信息

• INHIBITORS OF D-AMINO ACID OXIDASE
  申请人：Heffernan Michele L. R.

  公开号：US20100029737A1

  公开（公告）日：2010-02-04

  The present invention provides novel inhibitors of the enzyme D-amino acid oxidase. The compounds of the invention are useful for treating or preventing diseases and/or condition, wherein modulation of D-serine levels, and/or its oxidative products, is effective in ameliorating symptoms. The invention further provides methods of enhancing learning, memory and/or cognition. For example, the invention provides methods for treating or preventing loss of memory and/or cognition associated with neurodegenerative diseases, such as Alzheimer's disease. The invention further provides methods for preventing loss of neuronal function characteristic of neurodegenerative diseases. In addition, methods are provided for the treatment or prevention of neuropsychiatric diseases (e.g., schizophrenia) and for the treatment or prevention of pain and ataxia.

  本发明提供了新型D-氨基酸氧化酶酶的抑制剂。本发明的化合物可用于治疗或预防疾病和/或症状，其中调节D-丝氨酸水平和/或其氧化产物对缓解症状有效。本发明还提供了增强学习，记忆和/或认知的方法。例如，本发明提供了用于治疗或预防神经退行性疾病（如阿尔茨海默病）相关的记忆和/或认知丧失的方法。本发明还提供了预防神经退行性疾病特征性神经元功能丧失的方法。此外，还提供了用于治疗或预防神经精神疾病（例如，精神分裂症）和用于治疗或预防疼痛和共济失调的方法。
• Inhibitors of D-amino acid oxidase
  申请人：Sepracor, Inc.

  公开号：US07902252B2

  公开（公告）日：2011-03-08

  The present invention provides novel inhibitors of the enzyme D-amino acid oxidase. The compounds of the invention are useful for treating or preventing diseases and/or condition, wherein modulation of D-serine levels, and/or its oxidative products, is effective in ameliorating symptoms. The invention further provides methods of enhancing learning, memory and/or cognition. For example, the invention provides methods for treating or preventing loss of memory and/or cognition associated with neurodegenerative diseases, such as Alzheimer's disease. The invention further provides methods for preventing loss of neuronal function characteristic of neurodegenerative diseases. In addition, methods are provided for the treatment or prevention of neuropsychiatric diseases (e.g., schizophrenia) and for the treatment or prevention of pain and ataxia.

  本发明提供了新型D-氨基酸氧化酶的抑制剂。本发明的化合物可用于治疗或预防疾病和/或症状，其中调节D-丝氨酸水平及/或其氧化产物可有效缓解症状。此外，本发明还提供了增强学习、记忆和/或认知的方法。例如，本发明提供了用于治疗或预防神经退行性疾病（如阿尔茨海默病）相关的记忆和/或认知损失的方法。本发明还提供了预防神经退行性疾病特征性神经元功能丧失的方法。此外，还提供了治疗或预防神经精神疾病（如精神分裂症）以及治疗或预防疼痛和共济失调的方法。
• PHARMACEUTICAL COMPOSITION CONTAINING FUSED HETERO-RING DERIVATIVE
  申请人：Tachibana Yuuki

  公开号：US20120277238A1

  公开（公告）日：2012-11-01

  The present invention provides a compound which indicates a histamine H4 receptor modulating activity. A compound represented by a formula (I): wherein A ring is a ring represented by the following formula: wherein R 1 is substituted or unsubstituted alkyl, etc., W is —O—, etc., n is an integer of 0 to 6; X is —N(R 7 )— or —O—; R 7 is hydrogen, substituted or unsubstituted alkyl, etc.; Y is —C(R 8 )═ or —N═; R 8 is hydrogen, substituted or unsubstituted alkyl, etc.; Z is ═O, ═S, etc.; B ring is a ring represented by the following formula: wherein R 10 is each independently substituted or unsubstituted alkyl, halogen, hydroxy, substituted or unsubstituted alkyloxy, substituted or unsubstituted amino; R 11 , R 12a and R 12b are each independently hydrogen or substituted or unsubstituted alkyl, etc.; p is an integer of 0 to 4, or its pharmaceutically acceptable salt, or a solvate thereof.
• US7902252B2
  申请人：——

  公开号：US7902252B2

  公开（公告）日：2011-03-08
• [EN] INHIBITORS OF D-AMINO ACID OXIDASE<br/>[FR] INHIBITEURS DE LA D-AMINO ACIDE OXYDASE
  申请人：SEPRACOR INC

  公开号：WO2008089453A2

  公开（公告）日：2008-07-24

  (EN) The present invention provides novel inhibitors of the enzyme D- amino acid oxidase. The compounds of the invention are useful for treating or preventing diseases and/ or conditions, wherein modulation of D- serine levels, and/or its oxidative products, is effective in ameliorating symptoms. The invention further provides methods of enhancing learning, memory and/or cognition. For example, the invention provides methods for treating or preventing loss of memory and/or cognition associated with neurodegenerative diseases, such as Alzheimer's disease. The invention further provides methods for preventing loss of neuronal function characteristic of neurodegenerative diseases. In addition, methods are provided for the treatment or prevention of neuropsychiatry diseases (e.g., schizophrenia) and for the treatment or prevention of pain and ataxia.(FR) La présente invention concerne de nouveaux inhibiteurs de l'enzyme D-amino acide oxydase. Les composés de l'invention sont utiles pour le traitement ou la prévention de maladies et/ou d'affection, où la modulation de niveaux de D-sérine et/ou ces produits oxydatifs est efficace pour l'amélioration des symptômes. L'invention concerne en outre des procédés d'amélioration de l'apprentissage, de la mémoire et/ou de la commission. A titre d'exemple, l'invention propose des procédés pour le traitement ou la prévention de la perte de mémoire et/ou de la cognition associés à des maladies neurodégénératives, telles que la maladie d'Alzheimer. L'invention propose en outre des procédés pour la prévention de la perte de fonction neuronale caractéristique de maladies neurodégénératives. De plus, des procédés sont prévus pour le traitement et la prévention de maladies neuropsychiatriques (par exemple, schizophrénie) et pour le traitement ou la prévention de la douleur et de l'ataxie.